An observational study in Diabetic Foot Ulcer, sponsored by University Hospital, Bordeaux. Recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Diabetic Foot with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Diabetic Foot · France.
Among the 55 studies in Diabetic Foot with a site in France, this one is the 2nd largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2021, is one of 20 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 42nd registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →12 of the 55 studies in Diabetic Foot with a site in France are open now. Recruiting first, the newest first:
Solsius · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5
First in 2006; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 100 across 191 observational studies indexed under Diabetic Foot.
Median enrollment 82 across the 34 interventional studies, 140 across the 20 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 1 study filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetic Foot with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066801Assistance Publique - Hôpitaux de ParisBedside Bone Biopsy in Diabetic Foot Osteomyelitis | 2027-03 |
| NCT07910721SolsiusContinuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot. | 2027-04-10 |
| NCT07391995Centre Hospitalier Universitaire de NīmesNew Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis | 2027-06 |
| NCT05491577Centre Hospitalier Universitaire de NīmesFactors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot | 2027-07-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Diabetic Foot with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The worse prognosis observed in patients with Diabetic Foot Ulcer (DFU) has not been fully understood. Poor prognosis may be related to other conditions (inflammation, infectious disease, cancers) further to cardiovascular disease.
The aim of the study is to conduct the first prospective, observational and multi-centre cohort of patients with DFU in France, in order to evaluate the 5-years mortality rate, its causes and relevant prognostic determinants.
Diabetic foot ulcer (DFU) is one of the major complications frequently observed in patients with diabetes. DFU is the leading cause of non-traumatic lower-limb amputation (LLA), and it is associated with cognitive decline, worsening quality of life and substantial economic impact on French healthcare system. DFU is also associated with excess risk of premature death with significant decrease in life expectancy despite major improvement in medical care during last decades. The hypothesis of the study is that this worse prognosis seen in DFU patients may not be fully explained by a high cardiovascular risk, but mainly linked to different causes, including inflammatory, infectious and malignant conditions.
In addition, to conduct the first prospective, observational and multi-centre cohort of patients with DFU in France to evaluate the 5-years mortality rate, its causes and relevant prognostic determinants, the investigators will also assess all changes in health-related quality of life (HRQoL), and the economic impact related to DFU (cost of illness study) for the French healthcare system, using SNDS claims databases. A 3-year inclusion period will start during 2020, and each participant will be followed for 5 years or until death.
PDF study is designed to be the first French multicentre, observational and prospective cohort of patients with DFU referred from the community into secondary and tertiary care foot clinics.
Twenty-three French centres agreed to participate in this study. Each centre will recruit during the 3-year inclusion period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults with diabetes and DFU, defined as a foot skin ulceration or open LLA wound, measuring at least 5 mm of diameter, located below the malleolus, and induced by diabetic complications. In the case of an amputation before inclusion, the amputation stump will be considered as the main wound and not the wound that led to the amputation.
Exclusion Criteria:
DFU risk score
Construct a DFU risk score equation of all-death will be computed to determine individuals with the higher risk of worse outcomes.
Time frame: 5 years after inclusion
Survival without active index DFU
Time frame: At 3 and 12 months after inclusion day
Survival without recurrent index DFU
Time frame: At 12, 24, 36, 48, 60 months after inclusion day
Survival without major adverse limb events (MALE)
MALE is a composite of foot infection, non-traumatic lower-limb amputation (LLA), requirement of revascularization, whichever comes first. These components will be also considered individually.
Time frame: 5 years after inclusion
Survival without major macrovascular events (MACE)
MACE is a composite of non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, or cardiovascular death, whichever comes first.
Time frame: 5 years after inclusion
Survival without major microvascular events (MICE)
MICE is a composite of new-onset persistent macroalbuminuria, sustained 40% declined eGFR from baseline, ESRD, severe diabetic retinopathy or macular oedema requiring laser photocoagulation or intravitreal therapies, or diabetes-related blindness in either eye, whichever comes first.
Time frame: 5 years after inclusion
Not enrolling at this site — choose another above.
Started Nov 2021 (actual). Primary completion is estimated for Nov 2029, 96 months after the start.
Of 65 non-industry observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 94. This study's planned 96 months is above that.
Counting every sponsor, half of 90 studies reached it within 29 months; a quarter within 15 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →